ClinicalTrials.gg
CompletedNCT05221502Updated Aug 12, 2026Results posted

Safety and Efficacy Evaluation of 4-month Regimen of OPC-167832, Delamanid and Bedaquiline in Participants With Drug-Susceptible Pulmonary TB

A Phase 2 interventional study of Delamanid and Bedaquiline in Pulmonary TB, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 6 sites in South Africa. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-12.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
122
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing OPC-67683 in Tuberculosis, Pulmonary — 1 open to participants now, 4 under way, 2 of them phase 3. OPC-67683 · Tuberculosis, Pulmonary.

Enrollment
7th of 10
122 · median 208
Started
2022
with 1 other
Phase 2
6 of 10
1 open now
Registered
5th of 10
by date
Lead sponsor
2 of 10
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 10 studies testing OPC-67683 in Tuberculosis, Pulmonary, this one is the 7th largest by enrollment, is one of 2 that started in 2022, is one of 6 in phase 2, and was the 5th registered.

Tuberculosis, Pulmonary

319 studies on the registry are indexed under Tuberculosis, Pulmonary; 71 are open to participants now.

Browse Tuberculosis, Pulmonary studies →

Open to participants now

1 of the 10 studies testing OPC-67683 in Tuberculosis, Pulmonary is open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About OPC-67683

OPC-67683: first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 46 Tuberculosis, Pulmonary studies recruiting now, 22 (48%) set no upper age limit and 20 (43%) stop at 75 or younger; 11 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing OPC-67683 in Tuberculosis, Pulmonary, or all of them as a file.
02

Study summary

This trial will assess the safety and efficacy of OPC-167832 combined with delamanid and bedaquiline in participants with drug-susceptible tuberculosis (DS-TB) administered for 17 weeks compared to rifampin, isoniazid, ethambutol, pyrazinamide (RHEZ) administered for 26 weeks.

Read the detailed description

Eligible participants for this study have a diagnosis of pulmonary DS-TB.

This is a Phase 2b/c multicenter, open-label, randomized, dose-finding study, consisting of up to 26 weeks of treatment period.

Following a screening period of up to 14 days, eligible participants will be randomized in the study.

Randomization will be stratified by presence of bilateral cavitation on screening chest x-ray (yes or no). After the end of the treatment period, participants will be followed until 12 months post randomization.

03

Conditions studied

  • Pulmonary TB
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to provide written, prior to initiation of any trial-related procedures or treatments, and able, in the opinion of the investigator, to comply with all the requirements of the trial.
  2. Male or female participants between 18 and 65 years of age (inclusive) at the screening visit.
  3. Body weight ≥ 35.0 kg at the screening visit.
  4. Newly diagnosed, rifampin and isoniazid susceptible (on the screening sample) pulmonary TB.
  5. Able to spontaneously produce sputum.
  6. Females of (FOCBP) must agree to use 2 different approved methods of or remain abstinent throughout their participation in the trial and for 12 weeks after the last dose of IMP or dose of RHEZ.
  7. Male participants must agree to use 2 different approved methods of birth control or remain abstinent throughout their participation in the trial and for 12 weeks after the last dose of IMP or RHEZ.

Exclusion criteria

Exclusion Criteria:

  1. Participants are known or suspected of having resistance to rifampin, isoniazid, ethambutol, pyrazinamide, DLM, or BDQ either confirmed by the laboratory, or based on epidemiological history, at screening.
  2. Evidence of metabolic (for example, including ongoing or current hypokalemia [ie, potassium \<3.5 mEq/dL at screening]), gastrointestinal, neurological, psychiatric, endocrine or liver (eg, and C) disease; ; or other abnormalities (other than the indication being studied).
  3. History of, or current, clinically relevant cardiovascular disorder such as heart failure, coronary heart disease, uncontrolled hypertension, arrhythmia or symptom strongly suggestive of such a problem (for example, syncope or palpitations), tachyarrhythmia or status after myocardial infarction.
  4. Known bleeding disorders or family history of bleeding disorders.
  5. Any diseases or conditions in which the use of DLM, BDQ, OPC 167832, rifampin, isoniazid, pyrazinamide, or ethambutol is .
  6. Any prior treatment for M tuberculosis within the past 2 years.
  7. Any treatment with a drug active against M tuberculosis (eg, quinolones) within the 3 months prior to screening.
  8. Clinical evidence of severe extrapulmonary TB (eg, miliary TB, abdominal TB, urogenital TB, osteoarthritic TB, TB meningitis).
  9. Evidence of pulmonary silicosis, lung fibrosis, or other lung condition considered as severe by the investigator (other than TB). In particular, any underlying condition that could interfere with the assessment of x-ray images, sputum collection, or interpretation of sputum findings, or otherwise compromise the subject's participation in the trial.
  10. Any renal impairment characterized by /estimated (eGFR) of \< 60 mL/min/1.73 m2, or hepatic impairment characterized by or aspartate transaminase > 2.0 × of the clinical laboratory reference range or > 2.0 × upper limit of normal of the clinical laboratory reference range, at screening.
  11. Screening glucose (nonfasting) ≥ 200 mg/dL or glycosylated () ≥ 6.5%.
  12. > 450 msec in male participants (> 470 msec in female participants), atrioventricular block II or III, bi-fasicular block, at screening or current or history of clinically significant ventricular arrhythmias. Other abnormalities, if considered clinically significant by the investigator.
  13. Participants receiving any of the prohibited medications (see Section 6.5.1) within the specified periods or who would be likely to require prohibited concomitant therapy during the trial.
  14. Female participants who are breast-feeding or who have a positive pregnancy test result prior to receiving the first dose of IMP or RHEZ on Day 1.
  15. Current history of significant drug and/or alcohol abuse that is likely to result in poor adherence to trial requirements or that would pose a risk to the participant's well-being during the course of the trial.
  16. History of current hepatitis or carriers of hepatitis B surface antigen (HBsAg) and/or anti virus (HCV).
  17. Participants who test positive for cocaine or other drugs of abuse (excluding known prescription stimulants and other prescribed medications and marijuana) at screening are excluded. Detectable levels of alcohol, marijuana, barbiturates, or opiates in the drug screen are not exclusionary if, in the investigator's documented opinion, the participant does not meet , Fifth Edition criteria for moderate to severe substance use disorder and the positive test does not signal a clinical condition that would impact the safety of the participant or interpretation of the trial results, and participation is agreed to by the medical monitor prior to treatment.
  18. History of having taken an drug within 30 days preceding trial entry.
  19. A history of difficulty in donating blood.
  20. Donation of blood or plasma within 30 days prior to dosing.
  21. History of serious mental disorders that, in the opinion of the investigator, would exclude the participant from participating in this trial.
  22. Any known prior exposure to OPC-167832, DLM, or BDQ.
  23. Participants with significant medical comorbidities that in the opinion of the investigator, should not participate in the trial.
  24. Participants with score \< 60 will be excluded from the trial.
  25. Participants testing positive for active severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection at screening.
  26. Participants with co infection not on a stable anti-retroviral regimen consisting of tenofovir, emtricitabine/ lamivudine, dolutegravir (ie > 3 months), or who have a detectable viral load, or who have a \< 350 cells/mm3 will be excluded from the trial.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
122 participants (actual)

Study arms

  • Experimental
    Delamanid + Bedaquiline + OPC-167832 10 mg

    Participants will receive a combination regimen of delamanid, 300 mg, oral tablets, once daily (QD), bedaquiline, 400 mg, oral tablets, QD for 2 weeks, then 200 mg, thrice weekly (TIW) and OPC-167832, 10 mg, oral tablets, QD for a total of 17 weeks.

    Drug: Delamanid · Drug: Bedaquiline · Drug: OPC-167832 10 mg

  • Experimental
    Delamanid + Bedaquiline + OPC-167832 30 mg

    Participants will receive a combination regimen of delamanid, 300 mg, oral tablets, QD, bedaquiline, 400 mg, oral tablets, QD for 2 weeks, then 200 mg, TIW and OPC-167832, 30 mg, oral tablets, QD for a total of 17 weeks.

    Drug: Delamanid · Drug: Bedaquiline · Drug: OPC-167832 30 mg

  • Experimental
    Delamanid + Bedaquiline + OPC-167832 90 mg

    Participants will receive a combination regimen of delamanid, 300 mg, oral tablets, QD, bedaquiline, 400 mg, oral tablets, QD for 2 weeks, then 200 mg, TIW and OPC-167832, 90 mg, oral tablets, QD for a total of 17 weeks.

    Drug: Delamanid · Drug: Bedaquiline · Drug: OPC-167832 90 mg

  • Active comparator
    Rifampin, Isoniazid, Ethambutol, and Pyrazinamide (RHEZ)

    Participants will receive RHEZ, orally, QD for 8 weeks followed by 18 weeks of rifampin and isoniazid for a total of 26 weeks.

    Drug: RHEZ · Drug: Rifampin · Drug: Isoniazid

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, Severe TEAEs, TEAEs Related to Study Drug, TEAEs Leading to Study Discontinuation, TEAEs Leading to Death, and All Grade TEAEs Based on DAIDS Criteria

    An adverse event (AE) was defined as any untoward medical occurrence in a clinical trial participant administered an investigational medicinal product or trial treatment and which does not necessarily have a causal relationship with this treatment. TEAEs are AEs with an onset date on or after the start of treatment. Serious AE are AEs that leads to death, is life threatening, requires or prolongs hospitalization, significant disability, congenital anomaly or birth defect, and other medically important serious advent. AEs were graded on a severity 3-point scale as follows: Mild: Discomfort noticed, but no disruption to daily activity.; Moderate: Discomfort sufficient to reduce or affect normal daily activity.;Severe: Inability to work or perform normal daily activity. As pre-specified in statistical analysis plan (SAP),Division of AIDS (DAIDS v2.1) criteria was used and AEs graded as follows:Grade 1-Mild;Grade 2-Moderate;Grade 3-Severe;Grade 4-Life Threatening;Grade 5-Death.

    Time frame: From first dose of study drug up to end of follow up period (up to Week 52)

  2. Number of Participants With Potentially Clinically Relevant Laboratory Test Abnormalities

    Laboratory assessments included clinical chemistry (Albumin, Alkaline Phosphatase, Aspartate Aminotransferase, Total Bilirubin, Calcium, Creatinine, estimated Glomerular Filtration Rate (eGFR), Glucose, Fasting and Non-Fasting, Cholesterol, Inorganic Phosphorus, Magnesium, Potassium, Sodium, Triglycerides and Uric Acid), hematology (Activated Partial Thromboplastin Time, Prothrombin Time, Partial Thromboplastin Time, International Normalized Ratio (INR), Absolute CD4+ Count, Absolute Lymphocytes, Absolute Neutrophil Count, Hemoglobin, Platelet Count, White Blood Cell), and urinalysis (Urine Glucose, Blood and Protein). As pre-specified in statistical analysis plan (SAP), Division of AIDS (DAIDS) criteria was used and abnormalities were graded as follows:Grade 1 - Mild; Grade 2 - Moderate; Grade 3 - Severe; Grade 4 - Life Threatening; Grade 5 - Death. Laboratory values with DAIDS Grade ≥3 were considered as potentially clinically relevant abnormalities and are reported here.

    Time frame: Baseline up to end of follow up period (up to Week 52)

  3. Number of Participants With Potentially Clinically Relevant Abnormalities in the Vital Signs

    Vital signs measurements included systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate, body weight, and body temperature. Blood pressure (i.e., SBP, DBP) and heart rate were measured in the supine and sitting positions after the participant had been in each position for at least 3 minutes. The participants were categorized based on the clinically relevant vital sign values as per DAIDS criteria pre-specified in SAP. Each vital sign parameter was graded using the DAIDS criteria as follows: Grade 1 - Mild; Grade 2 - Moderate; Grade 3 - Severe; Grade 4 - Potentially Life Threatening; Grade 5 - Death. The categories with at least one participant with clinically significant value of any grade for vital signs are reported here.

    Time frame: Baseline up to end of follow up period (up to Week 52)

  4. Number of Participants With Potentially Clinically Relevant Electrocardiogram (ECG) Abnormalities

    3 ECGs were performed at baseline (Day -1) spaced 5 to 10 minutes apart, and 3 ECGs at all subsequent visits during the treatment and follow-up periods. The categories with at least one participant with clinically relevant ECG abnormalities are reported here.

    Time frame: Baseline up to end of follow up period (up to Week 52)

  5. Number of Participants With an AE Reported as DAIDS Grade 3 or Higher

    An AE was defined as any untoward medical occurrence in a clinical trial participant administered a treatment that does not necessarily have a causal relationship with the treatment. All AEs were graded on a 5-point scale according to DAIDS Table for Grading the Severity of Adult and Pediatric AEs as follows: Grade 1 - Mild; Grade 2 - Moderate; Grade 3 - Severe; Grade 4 - Life Threatening; Grade 5 - Death.

    Time frame: From first dose of study drug up to end of follow up period (up to approximately Week 52)

  6. Number of Participants With TEAEs Leading to Discontinuation of Treatment

    An AE was defined as any untoward medical occurrence in a clinical trial participant administered an investigational medicinal product or trial treatment and which does not necessarily have a causal relationship with this treatment. TEAEs are AEs with an onset date on or after the start of treatment.

    Time frame: From first dose of the study drug up to end of follow up period (up to approximately Week 52)

  7. Percentage of Participants Who Achieved Sputum Culture Conversion (SCC) in Mycobacteria Growth Indicator Tube® (MGIT) by End of Treatment (Week 17)

    A participant was classified as having achieved SCC if the participant achieved first 2 consecutive sputum cultures negative for growth of mycobacterium tuberculosis at least 1 week apart (±4 days) after his/her last sputum culture that was positive for growth, and did not have a positive sputum culture result in between, and by the end of the treatment. Efficacy was assessed by using the MGIT liquid culture system. 95% confidence interval (CI) was calculated using Clopper Pearson (exact) confidence interval model.

    Time frame: Week 17

  8. Percentage of Participants Who Achieved SCC in MGIT by End of Treatment (Week 26)

    A participant was classified as having achieved SCC if the participant achieved first 2 consecutive sputum cultures negative for growth of mycobacterium tuberculosis at least 1 week apart (±4 days) after his/her last sputum culture that was positive for growth, and did not have a positive sputum culture result in between, and by the end of the treatment. Efficacy was assessed by using the MGIT liquid culture system. 95% CI is calculated using Clopper Pearson (exact) confidence interval model.

    Time frame: Week 26

Secondary outcomes

  1. Percentage of Participants Who Achieved SCC in MGIT by the End of 8 Weeks of Treatment

    A participant was classified as having achieved SCC if he/she achieved first 2 consecutive sputum cultures negative for growth of mycobacterium tuberculosis at least 1 week apart (±4 days) after his/her last sputum culture that was positive for growth, and did not have a positive sputum culture result in between, and by the end of the 8 weeks of treatment. Efficacy was assessed by using the MGIT liquid culture system. 95% CI is calculated using Clopper Pearson (exact) confidence interval model.

    Time frame: Week 8

  2. Time to Detection of MGIT Cultures

    Time to detection of MGIT cultures was the time assessed, in days, when a sputum culture result was positive using the MGIT system during the routine 42-day incubation period. A longer time to detection represented a lower burden of mycobacterium tuberculosis (MTB) organisms present in the sputum.

    Time frame: Baseline up to Week 52

  3. Percentage of Participants Achieving Negative Sputum Lipoarabinomannan (LAM) by 8 Weeks of Treatment and by End of Treatment

    Sputum LAM concentrations were measured on up to 3 samples collected at baseline and postbaseline at Week 8 and at end of treatment. A participant was classified as having achieved negative sputum conversion in LAM if the participant has the first of 2 visits of at least 1 week apart with sputum LAM negative (below the lower limit of quantification) and without a positive sputum LAM result in between. Numeric sputum LAM concentration data was converted to a binary variable using the rule: if the sputum LAM concentration was less than 10 picograms per milliliter (pg/mL) then it was interpreted as a negative result. If the sputum LAM concentration was greater than or equal to 10 pg/mL then it was interpreted as positive result. SCC for LAM was considered to have been achieved if there were negative results at two consecutive visits with non-missing results. 95% CI was calculated using Clopper Pearson (exact) confidence interval model.

    Time frame: Week 8, and End of Treatment Period - Week 17 (for OPC-167832 arms) and Week 26 (for RHEZ arm)

  4. Percentage of Participants With Acquired Drug Resistance

    Acquired resistance was defined as a post-baseline resistant result at any timepoint after a baseline susceptible result. Baseline was defined as Day -1, if Day -1 was missing then Day 1 was used, if day 1 was missing then Week 1 was used. Resistance data was collected for streptomycin, isoniazid, rifampicin, ethambutol, pyrazinamide, bedaquiline and delamanid. Susceptibility testing (DST) for anti-TB medications was performed on positive M tuberculosis isolates from Day -1 or Day 1 cultures, and on the end of treatment sputum specimen. Percentage of participants who were susceptible at baseline and developed resistance to the indicated drug (class) at any post-baseline visits was summarized.

    Time frame: Baseline up to Week 52

  5. Time to Sputum Culture Conversion (SCC)

    Sputum culture conversion occurs when a participant has the first of 2 consecutive visits of at least 7 days apart with sputum cultures negative and without a positive sputum culture result in between, as well as no positive sputum culture after the negative results. If a participant had a positive MGIT culture result throughout the study period, then the participant was considered as not having achieved SCC within the period under consideration. The time to SCC in this case was censored. Time to SCC was calculated from date of first dose using MGIT cultures without the mitigation method measures.

    Time frame: From the first dose of the study up to the end of the follow-up period (up to Week 52)

Other outcomes

  1. Assess the Positron Emission Tomography/Computerized Axial Tomography (PET/CT) Imaging Response Over the Course of Treatment

    Positron emission tomography/computerized axial tomography (PET/CT) imaging changes over the course of treatment, using quantitative scan assessment.

    Time frame: Baseline to Week 26

  2. Evaluate the Ribosomal Ribonucleic Acid Synthesis Ratio (RS Ratio) Decline in Sputum

    The decline of ribosomal ribonucleic acid synthesis ratio (RS ratio - a ratio of spacers between the mRNA) in sputum over the course of trial.

    Time frame: Baseline to 12 months post randomization

  3. Assess Whole Blood Transcriptomic Signatures Previously Associated With TB Cure From Serum

    The change in whole blood transcriptomic signatures over the course of treatment will be evaluated using ROC curves for association with microbiological and clinical response.

    Time frame: Screening to 12 months post randomization

  4. The Proportion of Participants With Favorable Outcome at 12 Months Post Randomization

    The proportion of subjects with favorable outcome as compared to the 6 months post end of treatment and at 12 months post randomization.

    Time frame: Baseline to 12 months post randomization

  5. Number of Participants With Relapse at 12 Months Post Randomization

    Proportion of participants with relapse at 12 months post randomization.

    Time frame: Baseline to 12 months post randomization

07

Results

Posted Aug 12, 2026

Participant flow

Participants took part in the study at 8 clinical sites in South Africa from 12 April 2022 to 19 May 2024.

Participant flow — Overall Study
MilestoneDelamanid + Bedaquiline + OPC-167832 10 mgDelamanid + Bedaquiline + OPC-167832 30 mgDelamanid + Bedaquiline + OPC-167832 90 mgRHEZ
Started20423921
Safety analysis set20423821
Modified intent-to-treat (mitt) analysis set20423821
Completed20393821
Not completed0310
Withdrew: Death0100
Withdrew: Physician decision0010
Withdrew: Randomized by mistake with trial treatment0100
Withdrew: Other0100

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, Severe TEAEs, TEAEs Related to Study Drug, TEAEs Leading to Study Discontinuation, TEAEs Leading to Death, and All Grade TEAEs Based on DAIDS Criteria

An adverse event (AE) was defined as any untoward medical occurrence in a clinical trial participant administered an investigational medicinal product or trial treatment and which does not necessarily have a causal relationship with this treatment. TEAEs are AEs with an onset date on or after the start of treatment. Serious AE are AEs that leads to death, is life threatening, requires or prolongs hospitalization, significant disability, congenital anomaly or birth defect, and other medically important serious advent. AEs were graded on a severity 3-point scale as follows: Mild: Discomfort noticed, but no disruption to daily activity.; Moderate: Discomfort sufficient to reduce or affect normal daily activity.;Severe: Inability to work or perform normal daily activity. As pre-specified in statistical analysis plan (SAP),Division of AIDS (DAIDS v2.1) criteria was used and AEs graded as follows:Grade 1-Mild;Grade 2-Moderate;Grade 3-Severe;Grade 4-Life Threatening;Grade 5-Death.

Time frame:
From first dose of study drug up to end of follow up period (up to Week 52)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, Severe TEAEs, TEAEs Related to Study Drug, TEAEs Leading to Study Discontinuation, TEAEs Leading to Death, and All Grade TEAEs Based on DAIDS Criteria
ParticipantsDelamanid + Bedaquiline + OPC-167832 10 mgDelamanid + Bedaquiline + OPC-167832 30 mgDelamanid + Bedaquiline + OPC-167832 90 mgRHEZ
TEAE17373021
Serious TEAE2300
Severe TEAE3521
TEAE Related to Study Drug4856
TEAE Leading to Study Discontinuation0100
TEAE Leading to Death0100
DAIDS Grade 1 TEAE41298
DAIDS Grade 2 TEAE9191712
DAIDS Grade 3 TEAE4441
DAIDS Grade 4 TEAE0100
DAIDS Grade 5 TEAE0100
PrimaryNumber of Participants With Potentially Clinically Relevant Laboratory Test Abnormalities

Laboratory assessments included clinical chemistry (Albumin, Alkaline Phosphatase, Aspartate Aminotransferase, Total Bilirubin, Calcium, Creatinine, estimated Glomerular Filtration Rate (eGFR), Glucose, Fasting and Non-Fasting, Cholesterol, Inorganic Phosphorus, Magnesium, Potassium, Sodium, Triglycerides and Uric Acid), hematology (Activated Partial Thromboplastin Time, Prothrombin Time, Partial Thromboplastin Time, International Normalized Ratio (INR), Absolute CD4+ Count, Absolute Lymphocytes, Absolute Neutrophil Count, Hemoglobin, Platelet Count, White Blood Cell), and urinalysis (Urine Glucose, Blood and Protein). As pre-specified in statistical analysis plan (SAP), Division of AIDS (DAIDS) criteria was used and abnormalities were graded as follows:Grade 1 - Mild; Grade 2 - Moderate; Grade 3 - Severe; Grade 4 - Life Threatening; Grade 5 - Death. Laboratory values with DAIDS Grade ≥3 were considered as potentially clinically relevant abnormalities and are reported here.

Time frame:
Baseline up to end of follow up period (up to Week 52)
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Relevant Laboratory Test Abnormalities
ParticipantsDelamanid + Bedaquiline + OPC-167832 10 mgDelamanid + Bedaquiline + OPC-167832 30 mgDelamanid + Bedaquiline + OPC-167832 90 mgRHEZ
Alanine Aminotransferase (U/L): High: Grade 30001
Aspartate Aminotransferase (U/L): High: Grade 30121
Aspartate Aminotransferase (U/L): High: Grade 41010
Bilirubin (umol/L): High: Grade 30010
Bilirubin (umol/L): High: Grade 41000
Cholesterol (Total) (mmol/L): High: Grade 30010
Creatinine (umol/L): High: Grade 33351
eGFR (mL/min): Low: Grade 32680
Glucose (Non-Fasting) (mmol/L): High: Grade 30310
Glucose (Non-Fasting) (mmol/L): High: Grade 40000
Potassium (mmol/L): High: Grade 40100
Sodium (mmol/L): High: Grade 30100
Triglycerides (mmol/L): High Grade 30010
Hemoglobin (g/dL): All (Males or Females): Low: Grade 31220
Hemoglobin (g/dL): All (Males or Females): Low: Grade 40100
Lymphocytes (x10^9/L): Low: Grade 30010
Prothrombin Time (sec): High: Grade 30100
Urine Protein: Grade 30200
PrimaryNumber of Participants With Potentially Clinically Relevant Abnormalities in the Vital Signs

Vital signs measurements included systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate, body weight, and body temperature. Blood pressure (i.e., SBP, DBP) and heart rate were measured in the supine and sitting positions after the participant had been in each position for at least 3 minutes. The participants were categorized based on the clinically relevant vital sign values as per DAIDS criteria pre-specified in SAP. Each vital sign parameter was graded using the DAIDS criteria as follows: Grade 1 - Mild; Grade 2 - Moderate; Grade 3 - Severe; Grade 4 - Potentially Life Threatening; Grade 5 - Death. The categories with at least one participant with clinically significant value of any grade for vital signs are reported here.

Time frame:
Baseline up to end of follow up period (up to Week 52)
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Relevant Abnormalities in the Vital Signs
ParticipantsDelamanid + Bedaquiline + OPC-167832 10 mgDelamanid + Bedaquiline + OPC-167832 30 mgDelamanid + Bedaquiline + OPC-167832 90 mgRHEZ
Hypertension- DBP: Grade 188138
Hypertension- DBP: Grade 22431
Hypertension- DBP: Grade 31211
Hypertension- SBP: Grade 1810168
Hypertension- SBP: Grade 23222
Hypertension- SBP: Grade 31010
Body Temperature Increased: Grade 11322
Body Temperature Increased: Grade 20332
Body Temperature Increased: Grade 30001
Body Temperature Increased: Grade 40010
Body Weight Decreased: Grade 2 weight loss from baseline4541
Body Weight Decreased: Grade 3 body weight loss from baseline1001
PrimaryNumber of Participants With Potentially Clinically Relevant Electrocardiogram (ECG) Abnormalities

3 ECGs were performed at baseline (Day -1) spaced 5 to 10 minutes apart, and 3 ECGs at all subsequent visits during the treatment and follow-up periods. The categories with at least one participant with clinically relevant ECG abnormalities are reported here.

Time frame:
Baseline up to end of follow up period (up to Week 52)
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Relevant Electrocardiogram (ECG) Abnormalities
ParticipantsDelamanid + Bedaquiline + OPC-167832 10 mgDelamanid + Bedaquiline + OPC-167832 30 mgDelamanid + Bedaquiline + OPC-167832 90 mgRHEZ
First Degree AV Block: > 200 msec1630
Increase in QT: >450 msec4732
Increase in QT: >480 msec2000
Increase in QTcB: >450 msec51573
Increase in QTcB: >480 msec2400
Increase in QTcB: >60 Increase from baseline0210
Increase in QTcB: >=30 to <=60 Increase from baseline620135
Increase in QTcF: >450 msec5841
Increase in QTcF: >60 Increase from baseline0521
Increase in QTcF: >=30 to <=60 Increase from baseline13282711
RR High: > 1200 msec6763
RR Low: < 600 msec1456
Sinus Bradycardia: Heart Rate {HR} _Mean < 41 beats per minute {bpm}0100
Sinus Bradycardia: HR_Mean < 50 bpm5753
Sinus Tachycardia: HR_Mean > 100 bpm4456
PrimaryNumber of Participants With an AE Reported as DAIDS Grade 3 or Higher

An AE was defined as any untoward medical occurrence in a clinical trial participant administered a treatment that does not necessarily have a causal relationship with the treatment. All AEs were graded on a 5-point scale according to DAIDS Table for Grading the Severity of Adult and Pediatric AEs as follows: Grade 1 - Mild; Grade 2 - Moderate; Grade 3 - Severe; Grade 4 - Life Threatening; Grade 5 - Death.

Time frame:
From first dose of study drug up to end of follow up period (up to approximately Week 52)
Reported as:
Count of participants · Participants
Number of Participants With an AE Reported as DAIDS Grade 3 or Higher
ParticipantsDelamanid + Bedaquiline + OPC-167832 10 mgDelamanid + Bedaquiline + OPC-167832 30 mgDelamanid + Bedaquiline + OPC-167832 90 mgRHEZ
Number of Participants With an AE Reported as DAIDS Grade 3 or Higher4641
PrimaryNumber of Participants With TEAEs Leading to Discontinuation of Treatment

An AE was defined as any untoward medical occurrence in a clinical trial participant administered an investigational medicinal product or trial treatment and which does not necessarily have a causal relationship with this treatment. TEAEs are AEs with an onset date on or after the start of treatment.

Time frame:
From first dose of the study drug up to end of follow up period (up to approximately Week 52)
Reported as:
Count of participants · Participants
Number of Participants With TEAEs Leading to Discontinuation of Treatment
ParticipantsDelamanid + Bedaquiline + OPC-167832 10 mgDelamanid + Bedaquiline + OPC-167832 30 mgDelamanid + Bedaquiline + OPC-167832 90 mgRHEZ
Number of Participants With TEAEs Leading to Discontinuation of Treatment0100
PrimaryPercentage of Participants Who Achieved Sputum Culture Conversion (SCC) in Mycobacteria Growth Indicator Tube® (MGIT) by End of Treatment (Week 17)

A participant was classified as having achieved SCC if the participant achieved first 2 consecutive sputum cultures negative for growth of mycobacterium tuberculosis at least 1 week apart (±4 days) after his/her last sputum culture that was positive for growth, and did not have a positive sputum culture result in between, and by the end of the treatment. Efficacy was assessed by using the MGIT liquid culture system. 95% confidence interval (CI) was calculated using Clopper Pearson (exact) confidence interval model.

Time frame:
Week 17
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Sputum Culture Conversion (SCC) in Mycobacteria Growth Indicator Tube® (MGIT) by End of Treatment (Week 17)
percentage of participantsDelamanid + Bedaquiline + OPC-167832 10 mgDelamanid + Bedaquiline + OPC-167832 30 mgDelamanid + Bedaquiline + OPC-167832 90 mg
Percentage of Participants Who Achieved Sputum Culture Conversion (SCC) in Mycobacteria Growth Indicator Tube® (MGIT) by End of Treatment (Week 17)100.0 (83.2 to 100.0)92.9 (80.5 to 98.5)97.4 (86.2 to 99.9)
PrimaryPercentage of Participants Who Achieved SCC in MGIT by End of Treatment (Week 26)

A participant was classified as having achieved SCC if the participant achieved first 2 consecutive sputum cultures negative for growth of mycobacterium tuberculosis at least 1 week apart (±4 days) after his/her last sputum culture that was positive for growth, and did not have a positive sputum culture result in between, and by the end of the treatment. Efficacy was assessed by using the MGIT liquid culture system. 95% CI is calculated using Clopper Pearson (exact) confidence interval model.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved SCC in MGIT by End of Treatment (Week 26)
percentage of participantsRHEZ
Percentage of Participants Who Achieved SCC in MGIT by End of Treatment (Week 26)100.0 (83.9 to 100.0)
SecondaryPercentage of Participants Who Achieved SCC in MGIT by the End of 8 Weeks of Treatment

A participant was classified as having achieved SCC if he/she achieved first 2 consecutive sputum cultures negative for growth of mycobacterium tuberculosis at least 1 week apart (±4 days) after his/her last sputum culture that was positive for growth, and did not have a positive sputum culture result in between, and by the end of the 8 weeks of treatment. Efficacy was assessed by using the MGIT liquid culture system. 95% CI is calculated using Clopper Pearson (exact) confidence interval model.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved SCC in MGIT by the End of 8 Weeks of Treatment
percentage of participantsDelamanid + Bedaquiline + OPC-167832 10 mgDelamanid + Bedaquiline + OPC-167832 30 mgDelamanid + Bedaquiline + OPC-167832 90 mgRHEZ
Percentage of Participants Who Achieved SCC in MGIT by the End of 8 Weeks of Treatment40.0 (19.1 to 63.9)57.1 (41.0 to 72.3)50.0 (33.4 to 66.6)52.4 (29.8 to 74.3)
SecondaryTime to Detection of MGIT Cultures

Time to detection of MGIT cultures was the time assessed, in days, when a sputum culture result was positive using the MGIT system during the routine 42-day incubation period. A longer time to detection represented a lower burden of mycobacterium tuberculosis (MTB) organisms present in the sputum.

Time frame:
Baseline up to Week 52
Reported as:
Median · days
Time to Detection of MGIT Cultures
daysDelamanid + Bedaquiline + OPC-167832 10 mgDelamanid + Bedaquiline + OPC-167832 30 mgDelamanid + Bedaquiline + OPC-167832 90 mgRHEZ
Baseline5.7 (4 to 15)5.1 (3 to 42)5.3 (2 to 29)5.5 (4 to 12)
Week 18.5 (3 to 42)8.8 (5 to 16)10.4 (4 to 42)9.3 (6 to 17)
Week 29.9 (7 to 42)10.5 (5 to 42)11.9 (4 to 42)12.0 (6 to 42)
Week 312.6 (8 to 42)12.6 (5 to 42)15.5 (9 to 42)14.0 (8 to 42)
Week 412.6 (8 to 42)14.4 (4 to 42)18.1 (6 to 42)15.9 (9 to 42)
Week 519.3 (9 to 42)18.6 (9 to 42)21.9 (6 to 42)21.7 (11 to 42)
Week 619.0 (11 to 42)23.0 (9 to 42)22.9 (11 to 42)23.6 (11 to 42)
Week 720.1 (8 to 42)28.6 (11 to 42)32.6 (12 to 42)30.6 (13 to 42)
Week 835.2 (10 to 42)42.0 (11 to 42)42.0 (11 to 42)42.0 (7 to 42)
Week 1042.0 (13 to 42)42.0 (12 to 42)42.0 (4 to 42)42.0 (17 to 42)
Week 1242.0 (17 to 42)42.0 (16 to 42)42.0 (8 to 42)42.0 (24 to 42)
Week 1342.0 (42 to 42)42.0 (14 to 42)42.0 (18 to 42)42.0 (30 to 42)
Week 1542.0 (11 to 42)42.0 (15 to 42)42.0 (18 to 42)42.0 (36 to 42)
Week 1742.0 (42 to 42)42.0 (29 to 42)42.0 (17 to 42)42.0 (42 to 42)
Week 1942.0 (4 to 42)42.0 (42 to 42)42.0 (24 to 42)42.0 (42 to 42)
Week 2142.0 (42 to 42)42.0 (42 to 42)42.0 (42 to 42)42.0 (42 to 42)
Week 2342.0 (18 to 42)42.0 (42 to 42)42.0 (28 to 42)42.0 (42 to 42)
Week 2642.0 (9 to 42)42.0 (42 to 42)42.0 (6 to 42)42.0 (42 to 42)
Week 2842.0 (14 to 42)42.0 (42 to 42)42.0 (42 to 42)42.0 (42 to 42)
Week 3042.0 (23 to 42)42.0 (42 to 42)42.0 (42 to 42)42.0 (42 to 42)
Week 3442.0 (42 to 42)42.0 (12 to 42)42.0 (19 to 42)42.0 (16 to 42)
Week 3942.0 (42 to 42)42.0 (7 to 42)42.0 (14 to 42)42.0 (3 to 42)
Week 4342.0 (7 to 42)42.0 (4 to 42)42.0 (7 to 42)42.0 (19 to 42)
Week 4742.0 (7 to 42)42.0 (4 to 42)42.0 (16 to 42)42.0 (10 to 42)
Week 5242.0 (13 to 42)42.0 (13 to 42)42.0 (18 to 42)42.0 (42 to 42)
Early Termination—11.0 (11 to 11)——
SecondaryPercentage of Participants Achieving Negative Sputum Lipoarabinomannan (LAM) by 8 Weeks of Treatment and by End of Treatment

Sputum LAM concentrations were measured on up to 3 samples collected at baseline and postbaseline at Week 8 and at end of treatment. A participant was classified as having achieved negative sputum conversion in LAM if the participant has the first of 2 visits of at least 1 week apart with sputum LAM negative (below the lower limit of quantification) and without a positive sputum LAM result in between. Numeric sputum LAM concentration data was converted to a binary variable using the rule: if the sputum LAM concentration was less than 10 picograms per milliliter (pg/mL) then it was interpreted as a negative result. If the sputum LAM concentration was greater than or equal to 10 pg/mL then it was interpreted as positive result. SCC for LAM was considered to have been achieved if there were negative results at two consecutive visits with non-missing results. 95% CI was calculated using Clopper Pearson (exact) confidence interval model.

Time frame:
Week 8, and End of Treatment Period - Week 17 (for OPC-167832 arms) and Week 26 (for RHEZ arm)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Negative Sputum Lipoarabinomannan (LAM) by 8 Weeks of Treatment and by End of Treatment
percentage of participantsDelamanid + Bedaquiline + OPC-167832 10 mgDelamanid + Bedaquiline + OPC-167832 30 mgDelamanid + Bedaquiline + OPC-167832 90 mgRHEZ
At Week 80 (0 to 0)2.4 (0.1 to 12.6)0 (0 to 0)14.3 (3.0 to 36.3)
At End of Treatment - Week 17 and Week 2615.0 (3.2 to 37.9)14.3 (5.4 to 28.5)23.7 (11.4 to 40.2)23.8 (8.2 to 47.2)
SecondaryPercentage of Participants With Acquired Drug Resistance

Acquired resistance was defined as a post-baseline resistant result at any timepoint after a baseline susceptible result. Baseline was defined as Day -1, if Day -1 was missing then Day 1 was used, if day 1 was missing then Week 1 was used. Resistance data was collected for streptomycin, isoniazid, rifampicin, ethambutol, pyrazinamide, bedaquiline and delamanid. Susceptibility testing (DST) for anti-TB medications was performed on positive M tuberculosis isolates from Day -1 or Day 1 cultures, and on the end of treatment sputum specimen. Percentage of participants who were susceptible at baseline and developed resistance to the indicated drug (class) at any post-baseline visits was summarized.

Time frame:
Baseline up to Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With Acquired Drug Resistance
percentage of participantsDelamanid + Bedaquiline + OPC-167832 10 mgDelamanid + Bedaquiline + OPC-167832 30 mgDelamanid + Bedaquiline + OPC-167832 90 mgRHEZ
Percentage of Participants With Acquired Drug Resistance0000
SecondaryTime to Sputum Culture Conversion (SCC)

Sputum culture conversion occurs when a participant has the first of 2 consecutive visits of at least 7 days apart with sputum cultures negative and without a positive sputum culture result in between, as well as no positive sputum culture after the negative results. If a participant had a positive MGIT culture result throughout the study period, then the participant was considered as not having achieved SCC within the period under consideration. The time to SCC in this case was censored. Time to SCC was calculated from date of first dose using MGIT cultures without the mitigation method measures.

Time frame:
From the first dose of the study up to the end of the follow-up period (up to Week 52)
Reported as:
Median · days
Time to Sputum Culture Conversion (SCC)
daysDelamanid + Bedaquiline + OPC-167832 10 mgDelamanid + Bedaquiline + OPC-167832 30 mgDelamanid + Bedaquiline + OPC-167832 90 mgRHEZ
Time to Sputum Culture Conversion (SCC)70.0 (51.0 to 84.5)56.0 (49.0 to 84.0)69.5 (49.0 to 84.0)56.0 (48.0 to 71.0)
Other pre-specifiedAssess the Positron Emission Tomography/Computerized Axial Tomography (PET/CT) Imaging Response Over the Course of Treatment

Positron emission tomography/computerized axial tomography (PET/CT) imaging changes over the course of treatment, using quantitative scan assessment.

Time frame:
Baseline to Week 26

Results for this outcome have not been posted.

Other pre-specifiedEvaluate the Ribosomal Ribonucleic Acid Synthesis Ratio (RS Ratio) Decline in Sputum

The decline of ribosomal ribonucleic acid synthesis ratio (RS ratio - a ratio of spacers between the mRNA) in sputum over the course of trial.

Time frame:
Baseline to 12 months post randomization

Results for this outcome have not been posted.

Other pre-specifiedAssess Whole Blood Transcriptomic Signatures Previously Associated With TB Cure From Serum

The change in whole blood transcriptomic signatures over the course of treatment will be evaluated using ROC curves for association with microbiological and clinical response.

Time frame:
Screening to 12 months post randomization

Results for this outcome have not been posted.

Other pre-specifiedThe Proportion of Participants With Favorable Outcome at 12 Months Post Randomization

The proportion of subjects with favorable outcome as compared to the 6 months post end of treatment and at 12 months post randomization.

Time frame:
Baseline to 12 months post randomization

Results for this outcome have not been posted.

Other pre-specifiedNumber of Participants With Relapse at 12 Months Post Randomization

Proportion of participants with relapse at 12 months post randomization.

Time frame:
Baseline to 12 months post randomization

Results for this outcome have not been posted.

Adverse events

Collected over From first dose of the study drug up to end of follow up period (up to Week 52). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Delamanid + Bedaquiline + OPC-167832 10 mg0/20 (0%)2/20 (10%)17/20 (85%)
Delamanid + Bedaquiline + OPC-167832 30 mg1/42 (2.4%)3/42 (7.1%)31/42 (73.8%)
Delamanid + Bedaquiline + OPC-167832 90 mg0/38 (0%)0/38 (0%)25/38 (65.8%)
RHEZ0/21 (0%)0/21 (0%)20/21 (95.2%)
Most frequent serious events
Most frequent serious events
EventDelamanid + Bedaquiline + OPC-167832 10 mgDelamanid + Bedaquiline + OPC-167832 30 mgDelamanid + Bedaquiline + OPC-167832 90 mgRHEZ
Appendicitis perforatedInfections and infestations1/200/420/380/21
Localised infectionInfections and infestations1/200/420/380/21
PneumoniaInfections and infestations0/201/420/380/21
TuberculosisInfections and infestations0/201/420/380/21
HyperkalaemiaMetabolism and nutrition disorders0/201/420/380/21
MyelopathyNervous system disorders0/201/420/380/21
HaemoptysisRespiratory, thoracic and mediastinal disorders0/201/420/380/21
Most frequent other events
Showing 10 of 66
Most frequent other events
EventDelamanid + Bedaquiline + OPC-167832 10 mgDelamanid + Bedaquiline + OPC-167832 30 mgDelamanid + Bedaquiline + OPC-167832 90 mgRHEZ
Upper respiratory tract infectionInfections and infestations3/2013/4212/388/21
HeadacheNervous system disorders3/208/427/386/21
ArthralgiaMusculoskeletal and connective tissue disorders3/202/420/384/21
DiarrhoeaGastrointestinal disorders2/205/422/383/21
NauseaGastrointestinal disorders0/200/423/383/21
Lower respiratory tract infectionInfections and infestations2/200/422/383/21
Back painMusculoskeletal and connective tissue disorders2/205/422/380/21
Abdominal painGastrointestinal disorders2/201/421/381/21
Electrocardiogram QT prolongedInvestigations2/202/420/380/21
Abnormal loss of weightMetabolism and nutrition disorders2/200/420/380/21

Baseline characteristics

The randomized analysis set included all participants who were randomized into the trial.

Age, Continuous
Age, Continuous(years)Delamanid + Bedaquiline + OPC-167832 10 mgDelamanid + Bedaquiline + OPC-167832 30 mgDelamanid + Bedaquiline + OPC-167832 90 mgRHEZTotal
Mean37.7 ± 11.9032.8 ± 11.9233.2 ± 12.1332.7 ± 9.9133.7 ± 11.66
Sex: Female, Male
Sex: Female, Male(Participants)Delamanid + Bedaquiline + OPC-167832 10 mgDelamanid + Bedaquiline + OPC-167832 30 mgDelamanid + Bedaquiline + OPC-167832 90 mgRHEZTotal
Female61513943
Male1427261279
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Delamanid + Bedaquiline + OPC-167832 10 mgDelamanid + Bedaquiline + OPC-167832 30 mgDelamanid + Bedaquiline + OPC-167832 90 mgRHEZTotal
Race — Black or African American1327291483
Race — Other71510739
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Delamanid + Bedaquiline + OPC-167832 10 mgDelamanid + Bedaquiline + OPC-167832 30 mgDelamanid + Bedaquiline + OPC-167832 90 mgRHEZTotal
Ethnicity — Hispanic or Latino00000
Ethnicity — Not Hispanic or Latino20423921122
08

Study locations

6 sites
  • Aurum Institute - Tembisa Clinical Research Centre
    Tembisa, Gauteng 1632, South Africa
  • TASK Applied Science, Brooklyn Chest Hospital Premises
    Cape Town, 7100, South Africa
  • University of CapeTown Lung Center Institute
    Cape Town, 7700, South Africa
  • Themba Lethu Clinic Clinical HIV Research Unit (CHRU)
    Johannesburg, 2092, South Africa
  • Perinatal HIV Research Unit Tshepong Hospital Complex
    Klerksdorp, 2574, South Africa
  • Setshaba Research Center
    Pretoria, 0152, South Africa
09

References and documents

Publications

  • Dawson R, Diacon AH, Variava E, Moloantoa T, Brumskine W, Ngwanto T, Zuma-Gwala N, Osman A, Rassool M, Bennet JA, Liu Y, Xu R, Li W, Takuva S, Hafkin J. Efficacy and safety of a 4-month quabodepistat, delamanid, and bedaquiline regimen for drug-susceptible pulmonary tuberculosis: a multicentre, open-label, randomised, proof-of-concept, non-inferiority, phase 2b/c trial. Lancet Infect Dis. 2026 May 29:S1473-3099(26)00143-X. doi: 10.1016/S1473-3099(26)00143-X. Online ahead of print. PubMed 42214407 ↗
  • Dawson R, Diacon AH, Takuva S, Liu Y, Zheng B, Karwe V, Hafkin J. Quabodepistat in combination with delamanid and bedaquiline in participants with drug-susceptible pulmonary tuberculosis: protocol for a multicenter, phase 2b/c, open-label, randomized, dose-finding trial to evaluate safety and efficacy. Trials. 2024 Jan 19;25(1):70. doi: 10.1186/s13063-024-07912-5. PubMed 38243296 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/

Data sharing details ↗ · clinical-trials.otsuka.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2022 to primary completion in Apr 2024, 23 months.

Results were first posted in Aug 2026, 2 years 4 months after primary completion. A results delay was requested in Apr 2025.

Of 43 phase 2 interventional studies under Tuberculosis, Pulmonary, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 37. This study's 23 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2021
First posted
Feb 3, 2022
StartActual
Apr 12, 2022
Primary completionActual
Apr 8, 2024
CompletionActual
May 19, 2024
Results delay requested
Apr 5, 2025
Results first posted
Aug 12, 2026
Last update
Aug 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05221502
Collaborators
Bill and Melinda Gates Foundation
Responsible party
Sponsor
First posted
Feb 3, 2022
Start date
Apr 12, 2022
Primary completion
Apr 8, 2024
Completion
May 19, 2024
Results posted
Aug 12, 2026
Last update
Aug 12, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: OPC-67683 · Bedaquiline · Quabodepistat

Start the discussion